Senthil Radhakrishnan, Ph.D.
Massey Cancer Center research program membership
Cancer Molecular Genetics
Department of Pathology,
School of Medicine
PhD, University of Illinois at Chicago (2006)
MS, University of Illinois at Chicago (2002)
We are interested in understanding the cellular signaling pathways that are triggered in response to proteasome inhibitor drugs. We hope to devise new strategies to enhance the efficacy of proteasome inhibitors.
Disease focus of research
Autophagy,Cancer cell biology,Cell signaling,Drug discovery,Signal transduction,Targeted therapies
Published research (during tenure as a Massey Cancer Center member)
Search In PubMed